
If you don’t know a soul that’s bullish — and I imply flat-out optimistic — you could want some new pals. We will soon see the demise of the inverted
Continue ReadingCramer: These things could soon break the bulls’ manner, plus 4 stocks to buy
Ozempic drug to deal with diabetes. Courtesy: Ozempic In their most up-to-date earnings experiences, Novo Nordisk and Eli Lilly proved why they’re the undisputed heavyweights within the prizefight for management
Robert Galbraith | Reuters The Federal Trade Commission final week allowed Amgen to maneuver ahead with its $27.8 billion acquisition of Horizon Therapeutics underneath a settlement agreement – a transfer
The Amgen emblem is displayed outdoors Amgen headquarters on May 17, 2023 in Thousand Oaks, California. Mario Tama | Getty Images The Federal Trade Commission on Friday mentioned it has
Continue ReadingFTC allows Amgen to move forward with $27.8 billion Horizon Therapeutics acquisition
Rafael Henrique | Lightrocket | Getty Images CVS Health is partnering with drugmaker Sandoz to supply a close to similar model of the blockbuster arthritis therapy Humira that may promote
Continue ReadingCVS pushes into making cheaper versions of complex drugs with new discount Humira
Merck & Co. Inc. Januvia model medicine, used to deal with type2 diabetes, sit on a pharmacy shelf in Princeton, Illinois. Daniel Acker | Bloomberg | Getty Images Medicare is
Continue ReadingThese 10 medications are likely targets for Medicare price negotiations this fall
People collect at a water fountain in a park earlier than the Manhattan skyline in the east river in New York on July 26, 2023. Ed Jones | Afp |
Sheldon Cooper | Lightrocket | Getty Images Check out the firms making headlines in after-hours buying and selling. Amazon – The e-commerce big popped more than 7% in prolonged buying
In this photograph illustration, bins of the diabetes drug Ozempic relaxation on a pharmacy counter in Los Angeles, April 17, 2023. Mario Tama | Getty Images The European Union’s drug
It’s been a busy few days in the obesity-and-diabetes drug business, with Club holding Eli Lilly (LLY) and its most important rival Novo Nordisk (NVO) publishing probably game-changing trial outcomes.